ASCO 2025

Clinical insights from ASCO 2025 in non–small cell lung cancer, focusing on emerging data, novel therapies, and evolving treatment strategies. It emphasizes integrating key conference findings—including advances in targeted therapies and antibody-drug conjugates—into real-world clinical practice.

Ep. 3: How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MD, Estelamari Rodriguez, MD, MPH, Helena Yu, MD

Ep. 2: New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

Helena Yu, MD, Joshua Sabari, MD

EP. 1: Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

Estelamari Rodriguez, MD, MPH, Helena Yu, MD, Joshua Sabari, MD

MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

Estelamari Rodriguez, MD, MPH, Helena Yu, MD, Joshua Sabari, MD, Susan Scott, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD